335 related articles for article (PubMed ID: 25657307)
21. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
Diener JL; Daniel Lagassé HA; Duerschmied D; Merhi Y; Tanguay JF; Hutabarat R; Gilbert J; Wagner DD; Schaub R
J Thromb Haemost; 2009 Jul; 7(7):1155-62. PubMed ID: 19422452
[TBL] [Abstract][Full Text] [Related]
22. Anti-human VWF monoclonal antibody SZ-123 prevents arterial thrombus formation by inhibiting VWF-collagen and VWF-platelet interactions in Rhesus monkeys.
Zhao YM; Jiang M; Ji SD; He Y; Shen F; Li XM; Ruan CG
Biochem Pharmacol; 2013 Apr; 85(7):945-53. PubMed ID: 23295157
[TBL] [Abstract][Full Text] [Related]
23. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
Bae ON
Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
[TBL] [Abstract][Full Text] [Related]
24. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
[TBL] [Abstract][Full Text] [Related]
25. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
Oney S; Nimjee SM; Layzer J; Que-Gewirth N; Ginsburg D; Becker RC; Arepally G; Sullenger BA
Oligonucleotides; 2007; 17(3):265-74. PubMed ID: 17854267
[TBL] [Abstract][Full Text] [Related]
26. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
McClanahan TB; Hicks GW; Morrison AL; Peng YW; Janiczek-Dolphin N; Mertz TE; Sullivan ME; Morser J; Juneau PL; Leadley R
Eur J Pharmacol; 2001 Dec; 432(2-3):187-94. PubMed ID: 11740955
[TBL] [Abstract][Full Text] [Related]
27. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance venography in the diagnosis and management of May-Thurner syndrome.
Wolpert LM; Rahmani O; Stein B; Gallagher JJ; Drezner AD
Vasc Endovascular Surg; 2002; 36(1):51-7. PubMed ID: 12704525
[TBL] [Abstract][Full Text] [Related]
29. P-Selectin Inhibition Therapeutically Promotes Thrombus Resolution and Prevents Vein Wall Fibrosis Better than Enoxaparin and an Inhibitor to von Willebrand Factor.
Diaz JA; Wrobleski SK; Pechota AR; Hawley AE; Roelofs KJ; Doornbos NK; Gabriel JE; Reynolds G; Lester P; Londy F; Lowe S; Henke PK; Schaub RG; Wakefield TW; Myers DD
J Vasc Surg Venous Lymphat Disord; 2014 Jan; 2(1):114. PubMed ID: 26993008
[No Abstract] [Full Text] [Related]
30. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin ameliorates deep vein thrombosis in rabbits by regulating the fibrinolytic system.
Feng Y; Zhang F; Niu L; Zhang M
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):531-41. PubMed ID: 27273142
[TBL] [Abstract][Full Text] [Related]
32. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity.
Barstad RM; Stephens RW; Hamers MJ; Sakariassen KS
Thromb Haemost; 2000 Feb; 83(2):334-7. PubMed ID: 10739395
[TBL] [Abstract][Full Text] [Related]
33. von Willebrand Factor and Venous Thromboembolism: Pathogenic Link and Therapeutic Implications.
Calabrò P; Gragnano F; Golia E; Grove EL
Semin Thromb Hemost; 2018 Apr; 44(3):249-260. PubMed ID: 28898897
[TBL] [Abstract][Full Text] [Related]
34. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
35. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
Cosmi B
Curr Opin Mol Ther; 2009 Jun; 11(3):322-8. PubMed ID: 19479665
[TBL] [Abstract][Full Text] [Related]
36. The aptamer BT200 effectively inhibits von Willebrand factor (VWF) dependent platelet function after stimulated VWF release by desmopressin or endotoxin.
Kovacevic KD; Buchtele N; Schoergenhofer C; Derhaschnig U; Gelbenegger G; Brostjan C; Zhu S; Gilbert JC; Jilma B
Sci Rep; 2020 Jul; 10(1):11180. PubMed ID: 32636459
[TBL] [Abstract][Full Text] [Related]
37. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
[TBL] [Abstract][Full Text] [Related]
38. Stasis Promotes Erythrocyte Adhesion to von Willebrand Factor.
Smeets MWJ; Mourik MJ; Niessen HWM; Hordijk PL
Arterioscler Thromb Vasc Biol; 2017 Sep; 37(9):1618-1627. PubMed ID: 28775074
[TBL] [Abstract][Full Text] [Related]
39. Targeting von Willebrand factor and platelet glycoprotein Ib receptor.
Firbas C; Siller-Matula JM; Jilma B
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1689-701. PubMed ID: 21108551
[TBL] [Abstract][Full Text] [Related]
40. Vein wall re-endothelialization after deep vein thrombosis is improved with low-molecular-weight heparin.
Moaveni DK; Lynch EM; Luke C; Sood V; Upchurch GR; Wakefield TW; Henke PK
J Vasc Surg; 2008 Mar; 47(3):616-24. PubMed ID: 18295113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
